Verteporfin (CL 318952)

For research use only.

Catalog No.S1786 Synonyms: Visudyne

80 publications

Verteporfin (CL 318952) Chemical Structure

CAS No. 129497-78-5

Verteporfin (CL 318952, Visudyne) is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 424 In stock
USD 403 In stock
USD 1222 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Verteporfin (CL 318952) has been cited by 80 publications

Purity & Quality Control

Choose Selective VDA Inhibitors

Biological Activity

Description Verteporfin (CL 318952, Visudyne) is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.
Targets
VDA [1]
(Endothelial cells)
YAP/TEAD interaction [3]
()
In vitro

Verteporfin is about four times more efficient in absorbing light at wavelengths that penetrate tissues best (i.e., around 700 nm) and thus provides a much higher cytotoxic effect than hematoporphyrin (10 times more in human adherent cell lines). Verteporfin is lipophilic and is more readily taken up by malignant or activated cells, compared with normal or resting cells. Verteporfin binds with LDL to form a complex, which is then taken up into proliferating cells (e.g., neovascular endothelial cells) probably via LDL receptors and endocytosis. Verteporfin therapy achieves complete angiographic occlusion of the neovascular compartment by thrombosis of vascular channels, following selective endothelial damage. Verteporfin therapy selectively induces reproducible and isolated choriocapillary occlusion without alteration of overlying photoreceptors or ganglion cells, as shown by light and electron microscopy. [1] Verteporfin conbined with light rapidly exhibits apoptotic changes reflected by caspase-3 and caspase-9 activation and PARP cleavage in HL-60 cells, changes that are blocked by the general caspase inhibitor ZVAD.fmk. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HL-60 M1vHV2Z2dmO2aX;uJIF{e2G7 NVnBSWlOhjFyMDDu[{9uVA>? M1vB[mROW09? NFnpRWlqdmO{ZXHz[ZMhTE6DIH\yZYdu\W62YYTpc44hdGW4ZXzz MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODZyN{exNEc,OTB4MEe3NVA9N2F-
HL-60 MnTLZ5l1d3SxeHnjbZR6KGG|c3H5 MoPTglExOCCwZz;tUC=> M1iwbWROW09? M4LKfIlvcGmkaYTzJINmdGxidnnhZoltcXS7 M4T4PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyNkC3O|ExLz5zME[wO|cyODxxYU6=
Jurkat NUCwb5FPSXCxcITvd4l{KGG|c3H5 MYf+NlgxKG6P MmrxSG1UVw>? M{nXcYlv\HWlZYOgZUBD[2xvMj3k[ZBmdmSnboSgZZBweHSxc3nz NETQO2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUK0OVQyPSd-MUGyOFU1OTV:L3G+
RIF-1 NUXRSVg2TnWwY4Tpc44h[XO|YYm= MmXnNUDPxGdxbXy= MYTEUXNQ MULk[YNz\WG|ZYOgc5h6\2WwIHPvcpN2dXC2aX;u M1\abFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{NkG1O|E5Lz5zMk[xOVcyQDxxYU6=
RIF-1 NV7FOmRO[3m2b4TvfIlkcXS7IHHzd4F6 NHmzOHoyKM7:Zz;tcC=> Ml7jSG1UVw>? MoXv[IVkemWjc3WgeI8hOjBiwsGgOUUh[2WubDDzeZJ3cX[jbB?= NHvIbnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMk[xOVcyQCd-MUK2NVU4OTh:L3G+
SVEC4-10 NWHONmJ6TnWwY4Tpc44h[XO|YYm= Ml72NlAxKG6pL33s NV3hb3Z1TE2VTx?= NV;K[ldHcW6mdXPld{BucWO{b4T1ZpVt\SCmZYDvcJlu\XKrenH0bY9v M4LvOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NE[3NVA3Lz5zNkS2O|ExPjxxYU6=
SVEC4-10 M1f6[2Z2dmO2aX;uJIF{e2G7 M{DKXlIxOCCwZz;tcC=> NGDlTWRFVVOR NVXWS|F3cW6mdXPld{B{fHKnc4OgZYN1cW5iZnni[ZIh\m:{bXH0bY9v Mn;qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2NkexNFYoRjF4NE[3NVA3RC:jPh?=
ARPE-19 MXrjfZRwfG:6aXPpeJkh[XO|YYm= MVT+NE4yKM7:Zz;tcC=> NUPoTnh{TE2VTx?= NImwd4R{cG:5czDhJIRwe2VvZHXw[Y5l\W62IITvfIlkcXS7 M2fUXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUi3PVA2Lz5zNkm4O|kxPTxxYU6=
ARPE-19 NYDMRWxmTnWwY4Tpc44h[XO|YYm= Ml30NE4xOSEQvHevcYw> M3vJT2ROW09? NET6OJhqdmO{ZXHz[ZMhXkWJRjDhcoQhemWmdXPld{BRTUSIIHX4dJJme3Orb36= NX\4dJZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5PFc6ODVpPkG2PVg4QTB3PD;hQi=>
Y-79 Moq5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MkW2glEh|rypL33s MonXSG1UVw>? MXXk[YNz\WG|ZYOgdoV1cW6xYnzhd5RwdWFiY3XscEBxem:uaX\ldoF1cW:w MlLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3N{m3OlQoRjF6NUe5O|Y1RC:jPh?=
WERI-Rb1 M2PH[Gdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MorXglEh|rypL33s MUPEUXNQ MkX2[IVkemWjc3XzJJJmfGmwb3LsZZN1d22jIHPlcIwheHKxbHnm[ZJifGmxbh?= NVL4THY{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1O|k4PjRpPkG4OVc6PzZ2PD;hQi=>
RB247C3 MnHjS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXHiTWpUhjFizsznM41t NIrjcm1FVVOR M{DrcIRm[3KnYYPld{Bz\XSrbn;icIF{fG:vYTDj[YxtKHC{b3zp[oVz[XSrb36= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV5OUe2OEc,OTh3N{m3OlQ9N2F-
RB355 NF3COodIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MnzzglEh|rypL33s MVHEUXNQ Mn3Q[IVkemWjc3XzJJJmfGmwb3LsZZN1d22jIHPlcIwheHKxbHnm[ZJifGmxbh?= MmDrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3N{m3OlQoRjF6NUe5O|Y1RC:jPh?=
RB383 MlPrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1Xhc54yKM7:Zz;tcC=> NED3WXBFVVOR MXTk[YNz\WG|ZYOgdoV1cW6xYnzhd5RwdWFiY3XscEBxem:uaX\ldoF1cW:w MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV5OUe2OEc,OTh3N{m3OlQ9N2F-
hFibro MXXjfZRwfG:6aXPpeJkh[XO|YYm= NVToVGRVOC53INM1[{9udA>? NFmwPIVFVVOR NXy2WmM4\GWlcnXhd4V{KH[rYXLpcIl1gSCkeTC4Okw2LQ>? M3e4XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NESxNVE1Lz5{M{S0NVEyPDxxYU6=
pTMC NV3vWYQ4[3m2b4TvfIlkcXS7IHHzd4F6 MW[wMlUhyrWpL33s MVLEUXNQ NIK1Z|hl\WO{ZXHz[ZMhfmmjYnnsbZR6KGK7IEmyMlkm NVTCZ2x2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0OFEyOTRpPkKzOFQyOTF2PD;hQi=>
hTMC M2PMU4N6fG:2b4jpZ4l1gSCjc4PhfS=> MoDPNE42KML3Zz;tcC=> NI\FZ|BFVVOR M4DXdoRm[3KnYYPld{B3cWGkaXzpeJkh[nliOEiuPUU> NULycoVYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0OFEyOTRpPkKzOFQyOTF2PD;hQi=>
ARPE-19 MoS5Z5l1d3SxeHnjbZR6KGG|c3H5 MnT6NE42KML3Zz;tcC=> MoTpSG1UVw>? MmfO[IVkemWjc3XzJJZq[WKrbHn0fUBjgSB3NT61KS=> MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR2MUGxOEc,OjN2NEGxNVQ9N2F-
Panc-1 M37KVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NUHOd5BlOTBizszN M4e3PWROW09? NVrD[3R6cW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v M1HTWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2ME[5NFY6Lz5{NEC2PVA3QTxxYU6=
MIA PaCa-2 M3Xnfmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1LkbVExKM7:TR?= MUXEUXNQ NFTx[WRqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> MmPVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNkmwOlkoRjJ2ME[5NFY6RC:jPh?=
BxPC-3 MnnVS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NUXtNYREOTBizszN MUTEUXNQ NXLlZ49EcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDs[ZRmdHl? NYfDbGhlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOlkxPjlpPkK0NFY6ODZ7PD;hQi=>
SU86.86 M3z1[2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NGLCenEyOCEQvF2= M3fMeGROW09? M4D2UIlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBkd22ybHX0[Yx6 MlLBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNkmwOlkoRjJ2ME[5NFY6RC:jPh?=
MCF-7 MXPBeZRweGijZ4mgZZN{[Xl? MY[xNEDPxE1? Ml7lSG1UVw>? MkjMbY5pcWKrdIOg[4Vu[2m2YXLpcoUucW6mdXPl[EBifXSxcHjh[5k> MnTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNkmwOlkoRjJ2ME[5NFY6RC:jPh?=
WERI MlvBS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1P4c54yOCEQvHevcYw> MWHEUXNQ MYPpcohq[mm2czDndo94fGhib3[gdoV1cW6xYnzhd5RwdWFiY3XscJM> NHLJN5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizO|E1Oid-MkS4N|cyPDJ:L3G+
WERI NUCyOGVjTnWwY4Tpc44h[XO|YYm= NXvRfoNEhjFyIN88[{9udA>? NGS0TWVFVVOR NV23RWFy[myxY3vzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25? NVjHcogyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|cyPDJpPkK0PFM4OTR{PD;hQi=>
Y-79 NHTpN|ZHfW6ldHnvckBie3OjeR?= M16xfZ4yOCEQvHevcYw> MVnEUXNQ MU\icI9kc3NiY3XscEBkgWOuZTDwdo9oemW|c3nvci=> NHK4[|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizO|E1Oid-MkS4N|cyPDJ:L3G+
Y-79 MUjGeY5kfGmxbjDhd5NigQ>? NGPhZm9,OTBizsznM41t NHzZSZhFVVOR NEf1fXli\m[nY4TzJHlCWC2WRVHEJJBzd3SxLX;uZ49o\W6nIIDheIh4[Xl? NXHEVnZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|cyPDJpPkK0PFM4OTR{PD;hQi=>
Y-79 NGrtVlFHfW6ldHnvckBie3OjeR?= MXf+NVAh|rypL33s MWTEUXNQ Mnv4[I94di2{ZXf1cIF1\XNicHz1dolxd3SnbnP5JI1iemuncjDPR3QuPA>? M4jleFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEO3NVQzLz5{NEizO|E1OjxxYU6=
Phototoxicity assay MnLxRlE3TjFy NWXZdHdoOjRiaILz NIDFZ3dKSzVyIE2gNU4xPyEQvF2= NGqwW2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzOlM5QSd-MkexN|Y{QDl:L3G+
Phototoxicity assay M2SydWIyPkZzMB?= NI\RToQzPCCqcoO= NF\rdZpKSzVyIE2gNU4zKM7:TR?= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF|NkO4PUc,OjdzM{[zPFk9N2F-
Phototoxicity assay MUPBN|c2 NVrhfFlSOjRiaILz NIrHeWxKSzVyIE2gNk4xPiEQvF2= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF|NkO4PUc,OjdzM{[zPFk9N2F-
Dark toxicity assay MWPCNVZHOTB? NUfWPVdVPDhiaILz M1vRfmlEPTBiPTCyOE46OiEQvF2= NY\LUY5SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexN|Y{QDlpPkK3NVM3Ozh7PD;hQi=>
Dark toxicity assay NUO0Upd4SjF4RkGw MYq0PEBpenN? MkHGTWM2OCB;IEK1MlA{KM7:TR?= M37ROVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUO2N|g6Lz5{N{GzOlM5QTxxYU6=
Dark toxicity assay MUTBN|c2 MUO0PEBpenN? MmjrTWM2OCB;IEO2MlM{KM7:TR?= NYrqfYJZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexN|Y{QDlpPkK3NVM3Ozh7PD;hQi=>
qHTS assay MXXUR|Mz M2jZN5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCWQ{OyJINmdGy| MnPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay M37Q[XUuOiCRUx?= MojmdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFVvMjDPV{Bk\Wyucx?= MnH6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay MX7BOlc{ MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>? NW\YS4lFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay MVHERW9[ NFXoXFlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?= NF\PVWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
qHTS assay NYTudZJCW2Gxcz2y NHjFUG9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz MnnXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay NHLuR|ZDXC1|Nx?= MlLFdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy| MkniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay MnLTVmQ> MonVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{ MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
qHTS assay MVLTT{1PNVOK MnfQdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= NFOyNWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
qHTS assay NXfWUI1RSlRvMUK= MVzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN? NGPrRVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
qHTS assay MnH4UWchPjNiKE[tWGchWil? MkL6dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| NGjWd4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
qHTS assay NYXWU|h1V0iVLUWw NYfHN2FKeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=> MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
qHTS assay NIO2W|ZTcDRz NGjt[21yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?= M3HjTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay M1:zPXNLNUeETUK= MoXPdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= MofiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay NWrNXYxSW0tvTj3NRy=> MlnzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
qHTS assay NXvZem4xVEGQLUW= NXfOPFNkeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz NWfFSo1ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Antitumor assay M1XJUmIyPkZzMB?= M2HMWVIhdWdxa3e= Ml7PNkBpenN? NEHQW3lCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBDOT[IMUCgZ4VtdHNiaX3wcIFvfGWmIHnuJGM2P0KOL{[gcY92e2ViYYPz[ZN{\WRiYYOgeJVud3JiZ4Lve5RpKGmwaHnibZRqd25iYYSgNkBu\y:tZzygbZYh[WSvaX7pd5RmemWmIH\vdkAzKGi{czDmc4xtd3enZDDifUBqenKjZHnheIlwdiC5aYToJIxie2W{IHH0JFE2OCCML3PtK|Ih\m:{IEGwJI1qdnN? NEnlSnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzOlM5QSd-MkexN|Y{QDl:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-S6(S240/244) / p-4EBP1(S65); 

PubMed: 28202507     


KLE, EFE184 and NOU-1 were treated with Verteporfin (0.1 μM, 0.3 μM). After 36h, cell lysates were western blotted with indicated antibodies. Bands are from one of three independent experiments.

c-Myc / Bcl-2; 

PubMed: 29416644     


In CAL27 cell lines, the expression of BCL-2 and C-MYC proteins decreased with the increase of Verteporfin concentration. The presented columns are given as the means ± SD. *p < 0.05, **P < 0.01, ***p < 0.001.

ECAD / Vimentin / Sox2 / CD44 / CD133; 

PubMed: 30467925     


Yes-associated protein 1 (YAP1), E-cadherin, vimentin (epithelial-mesenchymal transition [EMT] pathway), SOX2 CD44 and CD133 (autophagy markers) were detected by western blot in control, verteporfin (1 μmol/L) and verteporfin + 231-taxol (0.5 μmol/L) resistance groups.

beta-catenin; 

PubMed: 28202507     


KLE, EFE184, NOU-1 and SKUT-2 were treated with 3 μM Verteporfin. After 24h, cell lysates were western blotted with indicated antibodies. Bands are from one of three independent experiments.

28202507 29416644 30467925
Growth inhibition assay
Cell viability; 

PubMed: 28042502     


A: Cell viability was determined by MTS assay after the UM cells were exposed to verteporfin for 72 hours. B: After treated with various concentrations of verteporfin for 24 hours, the UM cells (e.g., 92.1, Mel 270, Omm 1, Omm 2.3) were seeded in drug-free soft agar culture for 14 days. Colonies were counted. 

28042502
Immunofluorescence
YAP1; 

PubMed: 30254296     


Treatment of U343 cells with 5 μM VP between 1-8 h in both 21% and 1% O2 induced morphological changes. Scale bar represents 10 µm. VP: Verteporfin

Calreticulin; 

PubMed: 30254296     


Calreticulin (CRT) significantly increased in VP-treated (5 µM, 2 h) U87 cells in both 21% and 1% O2 indicating likely ER stress.

p-YAP(Y357); 

PubMed: 28404908     


Confocal images of HEC-1-B cells and organoids which were subjected to immunofluorescence detection of A. YAP and B. phospho-YAP after VP treatment. YAP and phospho-YAP are conjugated with goat anti-mouse and goat anti-rabbit Alexa flour secondary antibodies respectively. (A) Upper panel bar=63x and lower panel bar = 20x. (B) Upper panel bar=63x and lower panel bar = 20x.

30254296 28404908
In vivo Verteporfin can be used for angiographic visualization of choroidal vessels and CNV, which demonstrates that the photosensitizer accumulates rapidly in experimental CNV in monkeys. Verteporfin accumulates rapidly in the established vasculature of the choroid, RPE, and photoreceptors of rabbit eyes. Verteporfin reaches maximal tissue levels within 3 hours of intravenous injection, followed by a rapid decline within 24 hours in mice. Verteporfin is metabolized to a less active form in vivo and is cleared very rapidly, predominantly in the feces and a very small proportion excreted in urine. Verteporfin therapy effectively and selectively prevents fluorescein dye leakage from experimentally induced CNV in monkeys. [1]

Protocol

Solubility (25°C)

In vitro DMSO 100 mg/mL (139.12 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 718.79
Formula

C41H42N4O8

CAS No. 129497-78-5
Storage powder
in solvent
Synonyms Visudyne
Smiles COC(=O)CCC1=C(C)C2=CC3=NC(=CC4=C(C)C(=C([NH]4)C=C5N=C(C=C1[NH]2)C(=C5C)CCC(O)=O)C=C)C6=CC=C(C(C(=O)OC)C36C)C(=O)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04590664 Recruiting Drug: Verteporfin Glioblastoma|Recurrent Glioblastoma Emory University|National Cancer Institute (NCI) January 15 2021 Phase 1|Phase 2
NCT01846273 Completed Drug: Ranibizumab|Drug: Verteporfin PDT|Drug: Sham PDT Age-related Macular Degeneration|Polypoidal Choroidal Vasculopathy Novartis Pharmaceuticals|Novartis August 7 2013 Phase 4
NCT00423189 Terminated Drug: Ranibizumab (Lucentis)|Drug: 0.5mg ranibizumab Age-Related Macular Degeneration David M. Brown M.D.|Novartis Pharmaceuticals|Greater Houston Retina Research January 2007 Phase 4
NCT00403442 Terminated Device: Verteporfin Therapy/ Drug: Bevacizumab Macular Degeneration Vitreous -Retina- Macula Consultants of New York|QLT Inc. September 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VDA Signaling Pathway Map

Related VDA Products

Tags: buy Verteporfin (CL 318952) | Verteporfin (CL 318952) ic50 | Verteporfin (CL 318952) price | Verteporfin (CL 318952) cost | Verteporfin (CL 318952) solubility dmso | Verteporfin (CL 318952) purchase | Verteporfin (CL 318952) manufacturer | Verteporfin (CL 318952) research buy | Verteporfin (CL 318952) order | Verteporfin (CL 318952) mouse | Verteporfin (CL 318952) chemical structure | Verteporfin (CL 318952) mw | Verteporfin (CL 318952) molecular weight | Verteporfin (CL 318952) datasheet | Verteporfin (CL 318952) supplier | Verteporfin (CL 318952) in vitro | Verteporfin (CL 318952) cell line | Verteporfin (CL 318952) concentration | Verteporfin (CL 318952) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID